AC Immune Reports Q3 Revenue Growth of 244.7% Amid Continued Pipeline Expansion
AC Immune (ACIU) has released its third-quarter financial results, reporting a GAAP earnings per share (EPS) loss of CHF0.13. Despite the net loss, the company demonstrated significant top-line growth, with revenue reaching CHF 3.24 million, representing a substantial year-over-year increase of 244.7%. The financial results coincide with positive clinical momentum for the company's therapeutic pipeline. Recent developments include promising mid-stage trial data for its Parkinson’s disease drug candidate and early-stage trial data for an anti-inflammatory agent, driving investor interest in the firm's long-term development prospects.
Tickers: $ACIU
Topics: biotechnology clinical trial data earnings report revenue growth
Read the full article at Seeking Alpha
Part of the story Flint Reports Q3 Revenue Growth of 79.6% to C$267.22M (7 articles)